TRAVATAN Z (travoprost)
Travatan Z is an ophthalmic solution used for patients who have elevated pressure inside their eyes. It treats conditions such as open-angle glaucoma and ocular hypertension by lowering intraocular pressure. This medication helps patients with these conditions manage their eye health and reduce the risks associated with high internal eye pressure.
How TRAVATAN Z Works
This medication works by acting as a selective FP prostanoid receptor agonist. It is believed to lower eye pressure by increasing the uveoscleral outflow of fluid from the eye. While the exact mechanism is not fully understood, this increased drainage effectively reduces intraocular pressure.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2006-09-21
- Patent Cliff
- 2029
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
TRAVATAN Z Approval History
What TRAVATAN Z Treats
2 indicationsTRAVATAN Z is approved for 2 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Glaucoma
- Ocular Hypertension
TRAVATAN Z Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in TRAVATAN Z's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications TRAVATAN Z treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to TRAVATAN Z
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
11 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02390284 STOP-RGCD results posted | 20140587 R01EY014957 | Ph 3 | terminated | Stop Retinal Ganglion Cell Dysfunction Study |
| NCT04615403 results posted | IDOS-106-EXCH | Ph 2 | completed | Study of Exchange of Travoprost Intraocular Implant |
| NCT01444040 | GCF-027 | Ph 4 | completed | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost |
| NCT02914509 results posted | OTX-16-002 | Ph 3 | completed | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT |
| NCT00798694 results posted | 08-875 | Ph 4 | completed | How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used? |
| NCT01443988 | GCF-022 | Ph 4 | completed | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost |
| NCT01315574 BAK results posted | 11-007H | Ph 4 | terminated | Effects of Anti-Glaucoma Medications on the Ocular Surface |
| NCT02105311 | EC57-020-02-1 | Ph 4 | completed | Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure |
| NCT01254370 | NVG10E118 | Ph 2 | completed | Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease |
| NCT00705757 results posted | Pfizer GA6111AX | Ph 4 | completed | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
| NCT00799682 | GA6111ZH | Ph 4 | completed | Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TRAVATAN Z FDA Label Details
Indications & Usage
FDA Label (PDF)TRAVATAN Z is indicated for the treatment of Glaucoma; Ocular Hypertension.
Pro Intelligence Preview
Deep insights for TRAVATAN Z
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2029
- • 3 active patents
Trial Analysis
- • 3 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment